A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

• Status: Completed
• Trial end date: 2019-10-08
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7234292 administered intrathecally to adult patients with Huntington's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche; Ionis Pharmaceuticals, Inc.

Criteria

Key Inclusion Criteria:

• Must have completed dosing in ISIS 443139-CS1

Key Exclusion Criteria:

• Any new condition or worsening of existing condition that could make the patient unsuitable for participation or interfere with the patient participating in and/or completing the study